Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.61 -3.3%	$2.04	$1.11 ▼ $17.88	$52.61M	1.62	742,229 shs	371,126 shs
CNTX Context Therapeutics	$0.57 +1.6%	$0.74	$0.49 ▼ $2.75	$50.57M	1.86	296,634 shs	151,137 shs
PRLD Prelude Therapeutics	$0.86 -0.1%	$0.90	$0.61 ▼ $6.80	$48.62M	1.25	281,968 shs	108,690 shs
PRPH ProPhase Labs	$0.34 -8.3%	$0.34	$0.22 ▼ $4.49	$15.22M	-0.43	3.10 million shs	1.36 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	0.00%	-8.81%	+26.89%	+52.41%	-49.34%
CNTX Context Therapeutics	0.00%	-13.62%	-16.96%	-26.96%	-72.09%
PRLD Prelude Therapeutics	0.00%	-17.20%	-12.31%	+21.18%	-77.75%
PRPH ProPhase Labs	0.00%	+7.76%	+11.81%	+18.65%	-91.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	1.9344 of 5 stars	3.5	1.0	2.0	1.7	0.6
CNTX Context Therapeutics	2.3053 of 5 stars	3.6	2.0	0.6	1.7	1.3
PRLD Prelude Therapeutics	3.2406 of 5 stars	3.5	2.0	0.0	5.0	0.6
PRPH ProPhase Labs	0.4781 of 5 stars	0.0	3.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	3.00	Buy	$30.25	1,058.12% Upside
CNTX Context Therapeutics	3.20	Buy	$6.00	947.85% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.50	422.95% Upside
PRPH ProPhase Labs	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRPH, PRLD, ANVS, and CNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/8/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/29/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00
4/21/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/9/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/8/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/21/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$1.27 per share	N/A
PRLD Prelude Therapeutics	$7M	6.94	N/A	N/A	$2.39 per share	0.36
PRPH ProPhase Labs	$6.77M	2.06	N/A	N/A	$0.25 per share	1.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
CNTX Context Therapeutics	-$26.73M	-$0.31	N/A	N/A	N/A	N/A	-29.78%	-29.08%	8/6/2025 (Estimated)
PRLD Prelude Therapeutics	-$127.17M	-$1.69	N/A	N/A	N/A	N/A	-89.18%	-69.26%	8/11/2025 (Estimated)
PRPH ProPhase Labs	-$53.36M	-$1.26	N/A	N/A	N/A	-217.64%	-184.38%	-64.59%	8/13/2025 (Estimated)

Latest PRPH, PRLD, ANVS, and CNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	PRPH ProPhase Labs	-$0.18	-$0.12	+$0.06	$0.12	$2.45 million	$1.43 million
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	-$0.05	N/A	-$0.05	N/A	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A
3/21/2025	Q4 2024	ANVS Annovis Bio	-$0.38	-$0.43	-$0.05	-$0.43	N/A	N/A
3/20/2025	Q4 2024	CNTX Context Therapeutics	-$0.05	-$0.04	+$0.01	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
PRPH ProPhase Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	10.68	10.68
CNTX Context Therapeutics	N/A	48.81	48.81
PRLD Prelude Therapeutics	N/A	5.18	5.18
PRPH ProPhase Labs	0.30	1.03	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
CNTX Context Therapeutics	14.03%
PRLD Prelude Therapeutics	79.72%
PRPH ProPhase Labs	9.45%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
CNTX Context Therapeutics	2.80%
PRLD Prelude Therapeutics	63.90%
PRPH ProPhase Labs	20.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
CNTX Context Therapeutics	7	89.70 million	87.19 million	Not Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable
PRPH ProPhase Labs	130	41.54 million	32.94 million	Optionable

PRPH, PRLD, ANVS, and CNTX Headlines

Recent News About These Companies

ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer

June 17 at 7:30 AM | globenewswire.com

ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform

June 6, 2025 | globenewswire.com

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

May 21, 2025 | seekingalpha.com

Earnings call transcript: ProPhase Labs beats Q1 2025 EPS forecast, stock rises

May 21, 2025 | investing.com

ProPhase Labs Inc (PRPH) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges

May 21, 2025 | finance.yahoo.com

ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2025 Earnings Call Transcript

May 21, 2025 | msn.com

ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript

May 20, 2025 | seekingalpha.com

ProPhase Labs Q1 2025 Earnings Preview

May 20, 2025 | msn.com

ProPhase Labs's Earnings Outlook

May 20, 2025 | benzinga.com

ProPhase Labs Delays Form 10-Q Filing

May 16, 2025 | tipranks.com

ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

May 13, 2025 | globenewswire.com

Covid Test Lab Weighs Unusual Debt-Collection Plan: Bankruptcy

May 13, 2025 | wsj.com

ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024

April 2, 2025 | seekingalpha.com

ProPhase Labs reports FY24 EPS ($2.61) vs (98c) last year

April 1, 2025 | markets.businessinsider.com

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

ProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024

March 31, 2025 | globenewswire.com

ProPhase Labs FY 2024 Earnings Preview

March 28, 2025 | msn.com

6PRPH : An Overview of ProPhase Labs's Earnings

March 28, 2025 | benzinga.com

ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025

March 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH, PRLD, ANVS, and CNTX Company Descriptions

Annovis Bio NYSE:ANVS

$2.61 -0.09 (-3.26%)

Closing price 03:59 PM Eastern

Extended Trading

$2.73 +0.12 (+4.52%)

As of 07:44 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Context Therapeutics NASDAQ:CNTX

$0.57 +0.01 (+1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$0.60 +0.03 (+5.66%)

As of 07:10 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Prelude Therapeutics NASDAQ:PRLD

$0.86 0.00 (-0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$0.88 +0.02 (+2.85%)

As of 06:59 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

ProPhase Labs NASDAQ:PRPH

$0.34 -0.03 (-8.30%)

Closing price 04:00 PM Eastern

Extended Trading

$0.34 +0.00 (+0.30%)

As of 07:56 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time